NewAmsterdam Pharma Company NV Ordinary Shares

NewAmsterdam Pharma Company NV Ordinary Shares

Yahoo Finance • 12 days ago

Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026

We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Dr... Full story

Yahoo Finance • 21 days ago

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securit... Full story

Yahoo Finance • 21 days ago

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 2 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicin... Full story

Yahoo Finance • 3 months ago

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics(NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 6 months ago

National Presto, Garrett Motion, and More Stocks See Action From Activist Investors

Activists also report to the SEC on Universal Technical Institute, Impinj, Garrett Motion, and NewAmsterdam Pharma. Continue Reading... Full story

Yahoo Finance • 7 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medici... Full story

Yahoo Finance • 7 months ago

Biotech Stock Gets Booted in Latest Fund Update

Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story

Yahoo Finance • 7 months ago

Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ...

This article first appeared on GuruFocus. Insights into Stanley Druckenmiller (Trades, Portfolio)'s Third Quarter 2025 Portfolio Adjustments Warning! GuruFocus has detected 6 Warning Signs with NTRA. Is NTRA fairly valued? Test your thes... Full story

Yahoo Finance • 8 months ago

8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments... Full story

Yahoo Finance • 10 months ago

NewAmsterdam Pharma reports Q2 results

* NewAmsterdam Pharma press release [https://seekingalpha.com/pr/20190665-newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results] (NASDAQ:NAMS [https://seekingalpha.com/symbol/NAMS]): Q2 net loss of $1... Full story

Yahoo Finance • 10 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine... Full story

Yahoo Finance • 11 months ago

Obicetrapib shows promise in reducing Alzheimer's biomarkers

NAARDEN/MIAMI - NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its experimental drug obicetrapib significantly reduced plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, according to data from a prespecified ana... Full story

Yahoo Finance • 11 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting C... Full story

Yahoo Finance • 11 months ago

NewAmsterdam Pharma updates employment agreement with chief scientific officer

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced Friday that it has entered into an amended and restated employment agreement with Dr. John Kastelein, the company’s chief scientific officer and director. The agreement, effective as... Full story

Yahoo Finance • 11 months ago

NAMS Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of NewAmsterdam Pharma Company N V (Symbol: NAMS) crossed above their 200 day moving average of $20.32, changing hands as high as $21.26 per share. NewAmsterdam Pharma Company N V shares are currently tradi... Full story

Yahoo Finance • last year

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • last year

NewAmsterdam Pharma's SWOT analysis: stock poised for cardiovascular breakthrough

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is making waves in the cardiovascular drug market with its lead asset, obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor. As the company progresses through critical clinical t... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p<0.002) and... Full story

Yahoo Finance • last year

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicin... Full story